- Home
- MITT vs LRMR Comparison
MITT vs LRMR Comparison
Compare MITT & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MITT
- LRMR
- Stock Information
- Founded
- MITT 2011
- LRMR N/A
- Country
- MITT United States
- LRMR United States
- Employees
- MITT N/A
- LRMR N/A
- Industry
- MITT Real Estate Investment Trusts
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- MITT Real Estate
- LRMR Health Care
- Exchange
- MITT Nasdaq
- LRMR Nasdaq
- Market Cap
- MITT 204.8M
- LRMR 171.6M
- IPO Year
- MITT 2011
- LRMR N/A
- Fundamental
- Price
- MITT $7.53
- LRMR $2.67
- Analyst Decision
- MITT Strong Buy
- LRMR Strong Buy
- Analyst Count
- MITT 4
- LRMR 7
- Target Price
- MITT $8.50
- LRMR $18.86
- AVG Volume (30 Days)
- MITT 213.7K
- LRMR 1.2M
- Earning Date
- MITT 08-01-2025
- LRMR 08-06-2025
- Dividend Yield
- MITT 10.60%
- LRMR N/A
- EPS Growth
- MITT N/A
- LRMR N/A
- EPS
- MITT 0.89
- LRMR N/A
- Revenue
- MITT $79,955,000.00
- LRMR N/A
- Revenue This Year
- MITT N/A
- LRMR N/A
- Revenue Next Year
- MITT $9.01
- LRMR N/A
- P/E Ratio
- MITT $8.49
- LRMR N/A
- Revenue Growth
- MITT 13.91
- LRMR N/A
- 52 Week Low
- MITT $5.63
- LRMR $1.61
- 52 Week High
- MITT $7.95
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- MITT 60.17
- LRMR 56.20
- Support Level
- MITT $7.12
- LRMR $2.60
- Resistance Level
- MITT $7.51
- LRMR $3.02
- Average True Range (ATR)
- MITT 0.21
- LRMR 0.25
- MACD
- MITT -0.00
- LRMR 0.01
- Stochastic Oscillator
- MITT 83.33
- LRMR 51.35
About MITT AG Mortgage Investment Trust Inc.
AG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. It also focuses on investing in residential mortgage-backed securities (RMBS) issued or guaranteed by a government-sponsored enterprise.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.